Table 1.
Baseline data of the sacubitril-valsartan (SV) group and control group patients.
| SV | Control | P | |
|---|---|---|---|
| Number of patients | 51 | 51 | |
| Gender (Female/Male) | 16/35 | 16/35 | 1.0 |
| Age (years) (median, IQR) | 59 (51–69) | 59 (51–68) | 0.944 |
| BMI (Kg/m2) (median, IQR) | 25.3 (22.6–27.7) | 23.7 (22.2–26.4) | 0.085 |
| Dialysis modality (PD/HD) | 32/19 | 32/19 | 1.0 |
| Duration of dialysis (months) (median, IQR) |
24.8 (15.0–48.5) | 35.1 (16.3–57.3) | 0.345 |
| Hypertension, n (%) | 51 (100%) | 51 (100%) | 1.0 |
| Diabetes mellitus, n (%) | 32 (62.7%) | 25 (49%) | 0.163 |
| History of coronary disease, n (%) | 31 (60.8%) | 22 (43.1%) | 0.074 |
| History of heart infarctus, n (%) | 17 (33.3%) | 12 (23.5%) | 0.272 |
| Urine output (ml) (median, IQR) | 500 (100–1000) | 300 (0–800) | 0.165 |
| Causes of ESRD | |||
| Diabetes related kidney disease, n (%) | 26 (51.0%) | 26 (51.0%) | 0.543 |
| Glomerulonephritis, n (%) | 11 (21.6%) | 15 (29.4%) | |
| Hypertensive nephropathy, n (%) | 4 (7.8%) | 4 (7.8%) | |
| Polycystic kidney disease, n (%) | 2 (3.9%) | 3 (5.9%) | |
| Others | 8 (15.7%) | 3 (5.9%) | |
| Laboratory indices | |||
| Cholesterol, mmol/L (median, IQR) | 3.59 (3.06–4.23) | 3.83 (3.09–4.31) | 0.497 |
| LDL-C, mmol/L (median, IQR) | 1.73 (1.41–2.48) | 1.98 (1.54–2.29) | 0.886 |
| HDL-C, mmol/L (median, IQR) | 0.95 (0.73–1.16) | 0.88 (0.78–1.11) | 0.870 |
| Calcium, mmol/L (median, IQR) | 2.25 (2.13–2.36) | 2.23 (2.1–2.35) | 0.933 |
| Phosphorus, mmol/L (median, IQR) | 1.48 (1.24–1.90) | 1.62 (1.31–1.99) | 0.124 |
| PTH, pg/ml (median, IQR) | 173.9 (88.1–280.0) | 197.7 (125.5–384.6) | 0.119 |
| HbA1c, % (median, IQR) | 6.3 (5.4–7.3) | 6.3 (5.5–7.2) | 0.542 |
| Other medications | |||
| ACEI/ARB | 44 (86.3%)* | 46 (90.2%) | 0.539 |
| CCB | 43 (84.3%) | 30 (58.8%) | 0.004 |
| β-blocker | 31 (60.8%) | 27 (52.9%) | 0.424 |
| α-blocker | 18 (35.3%) | 11 (21.6%) | 0.124 |
| Diuretics | 40 (78.4%) | 32 (62.7%) | 0.082 |
Note: *ACEI/ARB treatment before the initiation of SV. SV: sacubitril-valsartan; BMI: body mass index; PD: peritoneal dialysis; HD: hemodialysis; ESRD: end-stage renal disease; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; CCB: calcium channel blocker; IQR: interquartile range.